Analyst Price Targets — NAUT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 28, 2025 1:10 pm | — | Guggenheim | $2.50 | $1.30 | TheFly | Nautilus Biotechnology price target lowered to $2.50 from $4 at Guggenheim |
| June 27, 2024 6:11 am | Subbu Nambi | Guggenheim | $6.00 | $2.29 | StreetInsider | Guggenheim Starts Nautilus Biotechnology (NAUT) at Buy |
Latest News for NAUT
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m.
Tom Yeung here with your Sunday Digest.
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of…
The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NAUT.
U.S. House Trading
No House trades found for NAUT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.